Resumen

Digitalis, particularly digoxin, have played an important role in the treatment of heart failure (HF) for over 200 years. In the past three decades, with the greatest knowledge of the pathophysiology of the disease, neurohumoral blockers were more effective in reducing morbidity and mortality and gained greater prominence. In addition, studies have suggested that digoxin does not reduce the risk of death and, in some cases, may even increase it. Thus, its use has been questioned and discouraged. This review aims to look at the pharmacology of digoxin, studies on its benefits and risks in patients with moderate to severe systolic HF and diastolic HF also. This review looks forward to answering the following question: Is there still room for the use of digitalis in HF?

Palabras clave: Digitalis digoxin systolic heart failure diastolic heart failure.

2010-07-13   |   824 visitas   |   Evalua este artículo 0 valoraciones

Vol. 5 Núm.2. Abril-Junio 2010 Pags. 59-64 Rev Insuf Cardíaca 2010; V(2)